Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Valproate augmentation for treatment-resistant schizophrenia
ISRCTN77257074Phase 3Terminated
- Sponsor
- King's College London
- Start
- Jan 2021
- Modality
- Small Molecules
01
Overview
Phase 3, randomised, double-blind trial in schizophrenia and schizoaffective disorder comparing Valproate augmentation + continuing antipsychotic treatment with Placebo + continuing antipsychotic treatment (2 arms). Primary endpoint: PANSS positive subscale at 12 months. Started Jan 2021; status: terminated.
02
Drugs
valproic acid
03
Conditions
schizophreniaschizoaffective disorder
Beyond the preview
Go deeper on ISRCTN77257074.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ISRCTN77257074.